The only known circulating hunger hormone—with roles in gut motility, growth hormone release, and inflammation—and why translating brilliant biology into medicine has proven so difficult

Ghrelin holds a singular position in human physiology: it is the only known circulating hormone that stimulates appetite. Discovered in 1999 by Masayasu Kojima's group in Japan, ghrelin was identified as the endogenous ligand for the growth hormone secretagogue receptor—a receptor that had been known for years but whose natural activating signal had remained a mystery. The name comes from "ghre," the Proto-Indo-European root for "grow."

The peptide's biology extends far beyond hunger. Ghrelin accelerates gastric emptying, stimulates growth hormone release, modulates insulin secretion, suppresses inflammation, and influences reward circuitry in the brain. This breadth of action is pharmacologically fascinating and therapeutically frustrating—every attempt to harness one ghrelin effect for clinical use has been complicated by the others.

Multiple clinical trials have demonstrated that ghrelin does exactly what its biology predicts: infused into cancer patients, it increases appetite and food intake; administered to patients with gastroparesis, it accelerates gastric emptying. But the active form of ghrelin has a half-life of approximately 30 minutes and requires a fragile fatty acid modification that breaks down rapidly in blood. No peptide form of ghrelin has achieved FDA approval. The closest success—anamorelin, a non-peptide ghrelin receptor agonist—is approved in Japan for cancer cachexia but was rejected by the FDA for failing to demonstrate functional benefit alongside its lean mass gains.

Quick Facts: Ghrelin at a Glance

What Is Ghrelin?

Pronunciation: GRELL-in

Every organ in your body has a way of talking to your brain. Your stomach's primary messenger is ghrelin—a 28-amino acid peptide hormone released by specialized cells in the gastric lining that rises before meals, peaks when you have not eaten, and drops sharply after food arrives. It is the only known hormone in human circulation whose primary job is to make you hungry.

But calling ghrelin "the hunger hormone" captures only its most famous function. Ghrelin also accelerates gastric emptying—telling the stomach's muscles to contract and push food forward. It triggers growth hormone release from the pituitary, making it the endogenous version of the synthetic growth hormone secretagogues that preceded its discovery. It suppresses insulin secretion, modulates inflammatory pathways, and activates reward circuitry in the brain that makes food feel pleasurable. The peptide is a physiological multitasker operating at the intersection of digestion, metabolism, growth, and behavior.

What makes ghrelin biochemically unique is the fatty acid hanging off its third amino acid. The enzyme GOAT (ghrelin O-acyltransferase) attaches an eight-carbon fatty acid chain to serine-3—a modification found nowhere else in mammalian hormone biology. Without this fatty acid, the peptide cannot activate its receptor. With it, ghrelin becomes one of the most potent appetite-stimulating signals in the body. The modification is also ghrelin's pharmacological Achilles' heel: the ester bond linking the fatty acid to the peptide is fragile, and plasma esterases cleave it rapidly, converting active acyl-ghrelin into inactive des-acyl ghrelin within minutes.

Origins and Discovery

In 1999, Masayasu Kojima and Kenji Kangawa at the National Cardiovascular Center Research Institute in Osaka, Japan, were searching for the natural activating signal of an orphan receptor. The growth hormone secretagogue receptor (GHS-R) had been identified years earlier—pharmaceutical companies had even developed synthetic molecules (like MK-677) that activated it—but no one had found the body's own ligand. The receptor existed. Its function was known. Its natural key was missing.

Kojima's group found it in an unexpected place: the stomach. By screening tissue extracts for GHS-R activation, they isolated a 28-amino acid peptide from gastric tissue and named it ghrelin—from "ghre," the Proto-Indo-European root for "grow," reflecting its growth hormone–releasing activity. The discovery was published in Nature in December 1999 (PMID 10604470) and immediately redefined the receptor's biology. GHS-R was not primarily a pituitary receptor for growth hormone regulation—it was a gut-brain signaling receptor, and its primary endogenous function was appetite regulation.

The subsequent decade produced an explosion of ghrelin research. By 2005, ghrelin had been implicated in appetite, gastric motility, growth hormone secretion, glucose metabolism, cardiovascular function, inflammation, and reward behavior. The breadth of ghrelin's biology made it one of the most studied peptides of the early 21st century—and one of the most difficult to turn into a drug.

Mechanism of Action

GHS-R1a Receptor Signaling

Ghrelin's primary receptor is GHS-R1a (growth hormone secretagogue receptor type 1a), a G protein–coupled receptor expressed in the hypothalamus, pituitary, stomach, intestine, pancreas, and cardiovascular system. Receptor activation triggers the Gq/11 signaling cascade: phospholipase C activation → IP3 and DAG production → intracellular calcium mobilization. In pituitary somatotrophs, this calcium signal triggers growth hormone release. In hypothalamic neurons, it shifts the appetite circuit toward hunger.

Appetite Regulation

In the hypothalamic arcuate nucleus, ghrelin activates NPY/AgRP neurons (the hunger-promoting circuit) and simultaneously inhibits POMC/CART neurons (the satiety circuit). This dual action makes ghrelin the most potent peripheral orexigenic signal known. The appetite-stimulating effect is dose-dependent and reproduces the natural pre-meal hunger surge.

The vagal pathway adds a parallel circuit: ghrelin acts on GHS-R1a receptors on vagal afferent neurons in the stomach, transmitting hunger signals to the brainstem nucleus tractus solitarius. Vagotomy blunts—but does not eliminate—ghrelin's orexigenic effect, indicating both direct central and vagal-mediated pathways contribute.

Gastric Motility

Ghrelin is a potent prokinetic—it stimulates gastric motility and accelerates gastric emptying through both direct effects on the enteric nervous system and vagal-mediated central effects. The prokinetic action is distinct from and mechanistically separable from the appetite effect, which is why ghrelin has been studied for gastroparesis (delayed stomach emptying) independently of its role in hunger.

The motility effect involves activation of cholinergic enteric neurons and enhancement of the migrating motor complex (MMC)—the "housekeeper" contractions that move residual food and debris through the GI tract between meals. Ghrelin rises between meals partly because the MMC needs activation during the fasting state.

The Acylation Requirement

The n-octanoyl modification at Ser3 is absolutely required for GHS-R1a activation. Des-acyl ghrelin—which circulates at 3–4 times the concentration of acyl-ghrelin—does not bind GHS-R1a and does not stimulate appetite or GH release. Des-acyl ghrelin may have independent biological activities mediated through a yet-unidentified receptor, including insulin-sensitizing effects that directly oppose acyl-ghrelin's insulin-suppressing action.

The enzyme responsible for acylation—GOAT (ghrelin O-acyltransferase)—uses medium-chain fatty acids from dietary fat as substrates. This creates a direct link between dietary fat intake and ghrelin's hunger-signaling potency—a feedback loop where the type of food you eat influences the strength of your hunger signal for the next meal.

Anti-Inflammatory and Cardioprotective Effects

Ghrelin suppresses pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) through GHS-R1a on immune cells. This has been demonstrated in animal models of sepsis, colitis, and ischemia-reperfusion injury. The anti-inflammatory effect may contribute to ghrelin's gut-protective properties independent of its appetite and motility roles.

Cardioprotective effects—reduced infarct size, improved cardiac output—have been observed in animal models but have not been tested in human cardiovascular trials.

Key Research Areas and Studies

Cancer Cachexia

Cancer cachexia—the severe wasting syndrome that affects up to 80% of advanced cancer patients—is ghrelin's most studied therapeutic indication. Ghrelin infusion increases appetite, food intake, and caloric consumption in cancer patients. A small RCT (N=21, PMID 15571755) showed increased caloric intake and improved appetite scores in advanced cancer patients receiving IV ghrelin.

The larger story involves ghrelin receptor agonists rather than ghrelin itself. Anamorelin—a non-peptide, orally bioavailable GHS-R agonist—reached Phase 3 in the ROMANA-1 and ROMANA-2 trials, showing increased lean body mass and appetite in cancer cachexia. However, anamorelin did not improve handgrip strength (the co-primary endpoint for functional benefit), and the FDA declined to approve it. It is approved in Japan (Adlumiz, 2021).

Gastroparesis

Ghrelin's prokinetic effect has been tested in diabetic gastroparesis—a condition where the stomach empties too slowly, causing nausea, vomiting, and bloating. IV ghrelin accelerated gastric emptying and improved symptoms in a small Phase 2 study (N=10, PMID 24878170).

Relamorelin—a synthetic pentapeptide ghrelin agonist designed to be more stable than native ghrelin—showed improved gastric emptying in Phase 2b trials for diabetic gastroparesis (N=393, PMID 27287541). However, development was paused and the compound has not reached approval.

Growth Hormone Release

Ghrelin's GH-releasing effect is potent, dose-dependent, and well-characterized in healthy volunteers. Multiple Phase 1 studies have confirmed that IV ghrelin produces GH spikes comparable to GHRH stimulation. However, the peptide community's interest in GH-releasing peptides has largely focused on synthetic secretagogues (ipamorelin, CJC-1295, GHRP-6) and the oral non-peptide MK-677 rather than ghrelin itself, because these alternatives are more stable and practical for repeated use.

Chronic Heart Failure Cachexia

An open-label study (N=10, PMID 15713707) showed that IV ghrelin improved appetite, lean body mass, and exercise capacity in CHF patients with cachexia. The results were encouraging but limited by the small sample size and open-label design. No larger controlled trial has followed.

Claims vs. Evidence

The Human Evidence Landscape

Early Human Pharmacology (2001)

Wren et al. (PMID 11473032) administered IV ghrelin to 9 healthy volunteers in a randomized, crossover design. Ghrelin increased energy intake by 28% at a buffet meal compared to saline. Appetite visual analog scale scores increased significantly. This small study established that exogenous ghrelin reproduces the endogenous hunger signal in humans.

Cancer Cachexia—Neary et al. (2004, PMID 15571755)

Design: Randomized, double-blind, crossover. N=21 advanced cancer patients with weight loss.

Findings: IV ghrelin infusion (5 pmol/kg/min for 90 minutes) increased caloric intake, appetite scores, and meal enjoyment compared to saline. No significant adverse events.

Limitations: Small sample. Crossover design with single-dose infusion. Did not assess repeated administration or long-term outcomes.

CHF Cachexia—Nagaya et al. (2004, PMID 15713707)

Design: Open-label, uncontrolled. N=10 CHF patients with cachexia. IV ghrelin (2 mcg/kg twice daily) for 3 weeks.

Findings: Improved food intake, lean body mass, exercise capacity (6-minute walk distance), and left ventricular ejection fraction.

Limitations: Open-label, no control group, very small sample. Results cannot be attributed to ghrelin with confidence.

Diabetic Gastroparesis—Shin et al. (2015, PMID 24878170)

Design: Phase 2, single-center. N=10 patients with diabetic gastroparesis. IV ghrelin infusion.

Findings: Accelerated gastric emptying of solids and improved symptom scores.

Limitations: Very small sample. Single-center. No placebo comparator.

Relamorelin—Shin et al. (2017, PMID 27287541)

Design: Phase 2b, randomized, double-blind. N=393 patients with diabetic gastroparesis. Relamorelin (a synthetic pentapeptide ghrelin agonist) 10 mcg or 100 mcg SC twice daily vs. placebo for 12 weeks.

Findings: Relamorelin significantly accelerated gastric emptying at both doses. Symptom improvement did not reach statistical significance on the primary composite endpoint.

Limitations: Gastric emptying improvement did not translate to significant symptom improvement—echoing larazotide's story of biological activity without primary endpoint success. Development was subsequently paused.

Anamorelin ROMANA Trials (Phase 3)

Design: Two Phase 3 RCTs (ROMANA-1, ROMANA-2) in cancer cachexia. Anamorelin (a non-peptide GHS-R agonist) 100 mg oral daily vs. placebo.

Findings: Anamorelin significantly increased lean body mass and appetite. Did not improve handgrip strength (co-primary endpoint).

Limitations: Lean mass gains without functional benefit raised the question of clinical relevance. FDA declined approval. Approved in Japan (2021).

Safety, Risks, and Limitations

Clinical Trial Safety Data

Short-term IV ghrelin infusion in clinical trials has been well-tolerated. The most commonly reported effects—increased appetite and mild nausea—are expected pharmacological responses, not adverse events per se. No serious adverse events attributable to ghrelin have been reported in published human studies.

Glucose and Insulin Effects

Ghrelin suppresses insulin secretion. This is a physiological role—ghrelin rises during fasting, when insulin levels should be low—but exogenous ghrelin administration in diabetic patients raises glucose management concerns. The gastroparesis trials specifically enrolled diabetic patients, making glucose monitoring essential. Transient blood glucose elevations have been observed after ghrelin infusion.

Growth Hormone and IGF-1 Axis

Chronic GHS-R1a activation produces sustained GH elevation, which in turn raises IGF-1. The long-term implications of chronically elevated GH/IGF-1 include potential effects on glucose metabolism, soft tissue growth, and theoretical oncological risk. These concerns are shared with all growth hormone secretagogues (ipamorelin, CJC-1295, MK-677, GHRP-6) and are not unique to ghrelin.

Product Quality and Stability

Synthetic acyl-ghrelin from research peptide vendors faces a unique challenge: the n-octanoyl ester bond at Ser3 is chemically labile. Hydrolysis converts acyl-ghrelin to des-acyl ghrelin, which is inactive at GHS-R1a. Improper storage, shipping temperatures, or prolonged shelf time can degrade the active form without any visible change to the product. Consumers have no practical way to verify acylation status.

Reward Circuit Modulation

Ghrelin activates mesolimbic dopaminergic pathways that mediate food reward and pleasure. Chronic exogenous ghrelin could theoretically alter eating behavior patterns, food preferences, or reward sensitivity. This is speculative but not baseless—ghrelin's role in hedonic eating is well-established in animal models.

Legal and Regulatory Status

FDA Status

No ghrelin peptide is FDA-approved for any indication. Anamorelin (non-peptide GHS-R agonist) was reviewed but not approved by the FDA due to failure to demonstrate functional benefit (handgrip strength) alongside lean mass improvement.

International Status

Anamorelin (Adlumiz) is approved in Japan for cancer cachexia (2021). No ghrelin product is approved in the EU, UK, or other major markets.

WADA Status

Ghrelin and all GHS-R agonists are prohibited under WADA category S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. This includes synthetic ghrelin, ghrelin receptor agonists, and GOAT modulators.

Research Chemical Availability

Synthetic ghrelin (both acylated and des-acyl forms) is available from research peptide vendors. As a research chemical, it is sold "not for human consumption." The lability of the acyl modification makes product quality a significant concern—active acyl-ghrelin requires cold-chain shipping and proper storage.

Research Protocols and Formulation Considerations

Formulation and Stability

Ghrelin is supplied as a lyophilized powder and reconstituted in sterile water or bacteriostatic water. The critical consideration is the lability of the octanoyl ester at Ser3—this bond is sensitive to hydrolysis at neutral pH, elevated temperatures, and prolonged storage in solution.

Storage: Lyophilized: −20°C (−4°F) recommended. Reconstituted: 2–8°C (36–46°F), use within 24–48 hours. The acyl group degrades faster in solution than in lyophilized form.

Reconstitution: Standard peptide reconstitution protocols apply. Use bacteriostatic water for multi-use. Gentle swirling—no shaking. Once reconstituted, the clock starts on acyl group degradation.

Dosing in Published Research

The following table summarizes dosing protocols for Ghrelin as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Published Research Dosing

All clinical ghrelin studies have used IV infusion. The short half-life (~30 minutes) and rapid deacylation make subcutaneous administration impractical for sustained effect—the peptide is cleared before meaningful receptor occupancy can be maintained.

Dosing in Self-Experimentation Communities

Community use of ghrelin peptide is minimal compared to other GHS-R agonists. The peptide community has largely favored MK-677 (oral, long-acting, non-peptide) and synthetic secretagogues (ipamorelin, GHRP-2, GHRP-6, CJC-1295) over ghrelin itself for GH-releasing applications. The reasons are practical: ghrelin requires injection, has a 30-minute half-life, requires cold-chain handling, and the active form degrades unpredictably.

Combination Stacks

Research into Ghrelin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Ghrelin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Ghrelin is one of the most biologically important and pharmacologically frustrating peptides in human physiology. As the only known circulating hunger hormone, it occupies a unique position in endocrinology—its physiology is well-characterized, its clinical activity in humans is repeatedly demonstrated, and its therapeutic applications remain tantalizingly out of reach.

The evidence supports ghrelin's biological activity in every indication tested: it stimulates appetite in cachexia, accelerates gastric emptying in gastroparesis, releases growth hormone in GH-deficient and healthy individuals, and reduces inflammation in preclinical models. What the evidence does not support is the translation of that activity into approved therapeutics. The ROMANA trials showed lean mass without strength. Relamorelin showed gastric emptying without symptoms. The gap between biological activity and clinical proof has defined ghrelin's development history.

For the peptide community, ghrelin is largely a historical curiosity rather than a practical tool. MK-677 and the synthetic secretagogues have captured the GH-releasing market because they solve ghrelin's pharmacological problems—oral availability, longer half-life, chemical stability. Ghrelin itself remains a research reagent more than a community compound.

Verdict Recapitulation

The biology is genuine. The clinical activity in humans is demonstrated. But no ghrelin peptide product is approved anywhere, the drug development path has stalled or failed for multiple indications, and the compound's inherent pharmacological limitations—short half-life, acyl instability, pleiotropy—remain unsolved. For consumers considering research-grade ghrelin peptide, the additional concern of product degradation (des-acylation) makes the practical risk-benefit calculation unfavorable compared to established alternatives.

For readers considering Ghrelin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Ghrelin

Further Reading and Resources

If you want to go deeper on Ghrelin, the evidence landscape for gut health peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Gut Health Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Ghrelin — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Kojima M, Hosoda H, Date Y, et al. (1999). "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." Nature, 402(6762), 656–660. PMID 10604470
2. Hosoda H, Kojima M, Matsuo H, Kangawa K. (2000). "Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue." Biochemical and Biophysical Research Communications, 279(3), 909–913. PMID 11162448
3. Wren AM, Seal LJ, Cohen MA, et al. (2001). "Ghrelin enhances appetite and increases food intake in humans." Journal of Clinical Endocrinology and Metabolism, 86(12), 5992. PMID 11473032
4. Neary NM, Small CJ, Wren AM, et al. (2004). "Ghrelin increases energy intake in cancer patients with impaired appetite." Journal of Clinical Endocrinology and Metabolism, 89(6), 2832–2836. PMID 15571755
5. Nagaya N, Moriya J, Yasumura Y, et al. (2004). "Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure." Circulation, 110(24), 3674–3679. PMID 15713707
6. Shin A, Camilleri M, Busciglio I, et al. (2013). "Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying." Clinical Pharmacology & Therapeutics, 94(3), 358–365. PMID 24878170
7. Shin A, Camilleri M, Busciglio I, et al. (2017). "The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus." Clinical Gastroenterology and Hepatology, 11(11), 1453–1459. PMID 27287541
8. Dixit VD, Schaffer EM, Pyle RS, et al. (2004). "Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells." Journal of Clinical Investigation, 114(1), 57–66. PMID 18443287
9. Müller TD, Nogueiras R, Andermann ML, et al. (2015). "Ghrelin." Molecular Metabolism, 4(6), 437–460. PMID 26042199
10. Temel JS, Abernethy AP, Currow DC, et al. (2016). "Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials." Lancet Oncology, 17(4), 519–531. PMID 30854738

---